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Available online 17 September 2018Background: Despite compelling data describing pro-regenerative effects of all-trans retinoic acid (ATRA) in pre-
clinical models of chronic obstructive pulmonary disease (COPD), clinical trials using retinoids for emphysema
patients have failed. Crucial information about the speciﬁc role of RA signaling in adult rodent and human lung
epithelial progenitor cells is largely missing.
Methods: Adult lung organoid cultures were generated from isolated primary mouse and human lung epithelial
cells, and incubatedwith pharmacological pathwaymodulators and recombinant proteins. Organoid number and
size were measured, and differentiation was assessed with quantitative immunoﬂuorescence and gene expres-
sion analyses.
Findings:We unexpectedly found that ATRA decreased lung organoid size, whereas RA pathway inhibition in-
creased mouse and human lung organoid size. RA pathway inhibition stimulated mouse lung epithelial prolifer-
ation via YAP pathway activation and epithelial-mesenchymal FGF signaling, while concomitantly suppressing
alveolar and airway differentiation. HDAC inhibition rescued differentiation in growth-augmented lung
organoids.
Interpretation: In contrast to prevailing notions, our study suggests that regenerative pharmacology using tran-
sient RA pathway inhibition followed by HDAC inhibition might hold promise to promote lung epithelial regen-
eration in diseased adult lung tissue.
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Endogenous lung regeneration is overwhelmed in chronic obstruc-
tive pulmonary disease (COPD), a widely prevalent syndrome clinically
deﬁned by airﬂow obstruction and progressive lung function decline
[1]. Pathologically, COPD is characterized by bronchitis, small airwaysmacology, Groningen
roningen, Groningen
dt), r.gosens@rug.nl
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an open access article underdisease, and destruction both of the smallest airways and of
gas-exchanging alveolar tissue (emphysema); these features stem
from a chronic inﬂammatory state due to long-term exposure to air-
borne pollutants including cigarette smoke. Currently, there are no
disease-modifying treatments able to halt or reverse structural defects
associated with COPD [1,2]. Novel pharmacological therapies to bolster
endogenous regenerative mechanisms are desperately needed to im-
prove patient quality of life and to ease the global healthcare burden.
The adult mammalian lung contains progenitor cell populations includ-
ing basal cells and secretory club cells in the airways, rare putative
multipotent stem cells in the distal airways, and alveolar type 2 (AT2)
cells within alveoli [3]; these populations can maintain and repair
mild damage, and to a limited extent, regenerate severe lung injurythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
Administration of retinoic acid promoted lung regeneration in ro-
dent models of adult chronic lung disease, yet clinical trials with
retinoids in COPD patients failed. The impact of RA pathwaymod-
ulation on adult lung epithelial stem cell function has been little
explored.
Added value of this study
In this studywe demonstrate that RA restricts adult lung organoid
growth, whereas RA pathway inhibition promoted lung epithelial
proliferation while suppressing differentiation. Moreover, HDAC
inhibition restored differentiation in growth-enhanced lung epithe-
lium. Our study thus sheds light on the role of RA signaling in adult
lung epithelial progenitor function.
Implications of all the available evidence
In contrast to prevailing ideas, our data suggest transient RA path-
way inhibition followed by HDAC inhibition may offer therapeutic
benefit for COPD patients.
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hold promise as a novel therapeutic strategy to augment lung regener-
ation in COPD.
The retinoic acid (RA) signaling pathway has emerged as a promis-
ing target for therapeutic regenerative pharmacology in adult chronic
lung diseases [13]. RA is derived from dietary vitamin A, which circu-
lates as retinol prior to entering target cells, where it is oxidized to all-
trans RA (ATRA) by retinol- and retinaldehyde- dehydrogenases
(RALDHs). ATRA is transcriptionally active via interactions with hetero-
dimers of RA receptors (RAR-α, −β, or –γ) and retinoid X receptors
(RXR-α,−β, or –γ) that bind to RA response elements (RAREs) in reg-
ulatory regions of target genes [14]. Studies inmice revealed that RA is a
critical regulator of both embryonic lung development and post-natal
alveolarization [15–19]. In vitro, ATRA stimulated human lung micro-
vascular angiogenesis [20] and induced lung ﬁbroblast elastin synthesis
[21]. In man, epidemiological evidence revealed associations between
vitamin A deﬁciency and reduced lung function in children that was al-
leviated bymaternal vitamin A supplementation [22]. RARβ variants are
associated with reduced adult lung function [23]. Moreover, RA path-
way perturbations correlated with emphysematous lung destruction
[20], and cultured lung ﬁbroblasts isolated from emphysema patients
exhibited impaired RA-induced elastin synthesis compared to non-
diseased control ﬁbroblasts [24], suggesting defective retinoid-driven
regeneration may contribute to COPD. Numerous pre-clinical studies
using in vivo rodent models of COPD/emphysema revealed the striking
ability of ATRA to induce structural remodeling consistent with alveolar
regeneration [25–32], however, the few clinical trials exploring RA or
retinoid analogues in patients with emphysema failed to meet primary
clinical endpoints [33–36]. Interpretation of these ﬁndings is hampered
by a poor understanding about the speciﬁc role of RA signaling in adult
lung epithelial progenitor cell function.
We addressed this knowledge gap using an adult lung organoid
model, which recapitulates critical processes during lung regeneration
[37]. Unexpectedly, we found that RA pathway stimulation decreased
lung organoid size and inhibited lung epithelial proliferation. In con-
trast, RA pathway inhibition promoted epithelial proliferation in
mouse lung organoids and in organoids derived from lung tissue from
COPD patients. In mouse lung organoids, augmented proliferation in-
duced by RA inhibition occurred with a concomitant suppression ofairway and alveolar epithelial differentiation, and was mediated by
yes-associated protein (YAP) pathway activation and ﬁbroblast-
epithelial ﬁbroblast growth factor (FGF) signaling. Histone deacetylase
(HDAC) inhibition combined with ATRA was identiﬁed as a potential
strategy to restore differentiation in adult lung epithelial cells.
2. Materials and methods
2.1. Reagents
Pharmacological agents used: All-trans retinoic acid ([ATRA] Sigma
Aldrich, Poole, UK #R2625), BMS493 (Tocris, Bristol, UK #3509),
CH5183284 (Selleck Chem, Munich, Germany #S7665), Verteporﬁn
(Sigma #SML0534, kindly provided by Dr. Ruud Bank, UMCG), SAHA
(Tocris #4652). Pharmacological agents were stored as stock solution
in dimethyl sulfoxide (DMSO) at -20 °C. Prior to treatment, agents
were further diluted in DMSO so that the volume added to culture
was equal across treatment groups. Equal volumes of DMSO
were added for vehicle control. Recombinant proteins used: FGF7
(R&D Systems, Abingdon, UK #251-KG), FGF10 (R&D Systems #345-
KG). Recombinant proteins were reconstituted in sterile ﬁltered PBS
with 0·1% (w/v) BSA and stored at -20 °C.
2.2. Ethics
All animal experiments were performed according to the Ethics
Committee guidelines of the University of Groningen. Human lung tis-
sue specimens were obtained with full informed consent from patients
undergoing lung volume reduction surgery or lung transplantation at
University of Medical Center Groningen (UMCG). The study protocol
was consistentwith the Research Code of the UniversityMedical Center
Groningen (https://www.umcg.nl/EN/Research/Researchers/General/
ResearchCode) and national ethical and professional guidelines (“Code
of conduct; Dutch federation of biomedical scientiﬁc societies”, htttp://
www.federa.org). All tissue samples were anonymized prior to use.
2.3. Cell culture
Mlg mouse lung ﬁbroblasts ([MLg2908, CCL206], ATCC, Wesel,
Germany) were maintained in DMEM/F12 medium (Life technologies,
Carlsbad, USA) supplemented with 10% fetal bovine serum (FBS, PAA
Laboratories, Pasching, Austria), penicillin/streptomycin (100 U/ml),
glutamine (1%, Life Technologies #35050–061) and Amphotericin B
(1×, Gibco). MRC5 human lung ﬁbroblasts (ATCC #CCL-171) were
maintained in F12 medium supplemented with 10% FBS, penicillin/
streptomycin (100 U/ml), glutamine (1%) and Amphotericin B (1×).
Cells were maintained at 37 °C in a humidiﬁed incubator with 5% CO2.
Prior to organoid culture, Mlg or MRC5 cells at 90% conﬂuence
were proliferation-inactivated in medium containing mitomycin C
(10 μg/ml, Sigma #M4287) for 2 h, followed by 3 washes in warm PBS
(Life technologies) and trypsinization.
2.4. Lung epithelial cell isolation
Epithelial cells were isolated from adult mouse lung with antibody-
conjugated magnetic beads (microbeads) as previously described
[38,39]. Pathogen-free wild type C57BL/6 N mice (minimum 8 weeks
old) were anaesthetized and sacriﬁced, lungs were ﬂushed with PBS
and instilled with low-melt agarose (Sigma #A9414) and dispase (BD
Biosciences, Oxford, UK #354235) and incubated at room temperature
for 45min. Trachea and extrapulmonary airwayswere removed, and re-
maining lobes were homogenized to single-cell suspension in DMEM
containing DNase1 (Applichem, Germany #A3778). Suspension was
passed through nylon ﬁlters and incubated with CD45 (Miltenyi Biotec,
Teterow, Germany #130–052-301) and CD31 (Miltenyi, #130–097-
418) microbeads, and then passed through LS columns (Miltenyi
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EpCAM (CD326) microbeads (Miltenyi #130–105-958) for epithelial
cell positive selection with LS columns. Mouse lung EpCAM+ cells
were resuspended in DMEMwith 10% FBS, and seeded intoMatrigel im-
mediately after isolation with equivalent numbers of Mlg cells as
described in the next section. Human lung epithelial cells were isolated
from lung tissue specimens obtained from 3 GOLD stage IV COPD pa-
tients undergoing lung transplantation, and 1 GOLD stage II COPD pa-
tient undergoing lung tumor resection (patient characteristics in
Table S1). Peripheral lung tissue was homogenized overnight at 4 °C
in EDTA (Gibco) containing 0·25% trypsin, penicillin/streptomycin
(100 U/ml), Collagenase A (2 mg/ml, Roche) and DNase I
(0·04 mg/ml, Sigma). The resulting suspension was ﬁltered prior to in-
cubation with EpCAM microbeads (Miltenyi #130–061-101) and posi-
tive selection with LS columns. Human EpCAM+ cells were seeded
into the Matrigel assay immediately after isolation with equivalent
numbers of MRC5 cells.
2.5. Lung organoid culture
The lung organoid (spheroid) assay is based on published protocols
with slight modiﬁcations [5,40,41]. Equivalent numbers of EpCAM+
cells and ﬁbroblasts were seeded per insert in 100 μl growth factor-
reduced Matrigel (Fisher Scientiﬁc, Landsmeer, The Netherlands
#11523550) diluted 1:1 with DMEM/F12 containing 10% FBS into
transwell inserts for 24-well plates (Thermo Fischer Scientiﬁc, Wal-
tham, USA 10421761). For mouse lung organoid cultures, 20,000
mouse lung EpCAM+ cells were seeded with 20,000 Mlg cells; for
human lung organoid cultures, 3500–30,000 human lung EpCAM+
cells were seeded with 3500–30,000 MRC5 cells. Mouse lung organoid
cultures were maintained in DMEM/F12 containing 5% FBS, penicillin/
streptomycin (100 U/ml), glutamine (1%), Amphotericin B (1×),
insulin-transferrin‑selenium (1×, Gibco #15290018), recombinant
mouse EGF (0·025 μg/ml, Sigma #SRP3196), Cholera toxin (0·1 μg/ml,
Sigma #C8052) and bovine pituitary extract (30 μg/ml, Sigma
#P1476). ATRA was freshly added to organoid culture media
(0·01 μM, Sigma #R2625) for all experiments except for those investi-
gating effects of ATRA, in which ATRA was added at the indicated con-
centrations. Y-27632 (10 μM, Tocris #1254) was added for the ﬁrst
48 h of culture. Human lung organoids were maintained in SAGM
(Promocell #C21170) supplemented with 1% FBS, with the indicated
ATRA or RA inhibitor treatments. All organoid culturesweremaintained
at 37 °C in a humidiﬁed incubator with 5% CO2. Medium was refreshed
every 2–3 days.
2.6. Quantiﬁcation of organoid number, size and differentiation
To quantify organoid colony forming efﬁciency, total number of
organoids per well was manually counted 7 days after seeding using a
light microscope at 10× magniﬁcation. Data points represent the
mean of 2 wells per condition per independent experiment. Organoid
diameter was measured 14 days after seeding for mouse cultures, and
21 days after seeding for human cultures, with a light microscope
connected to NIS-Elements software (Nikon). All organoids within N3
random ﬁelds of view were measured per well; 2 wells were analyzed
per condition per independent experiment. Human lung organoids
were deﬁned as N50 μm diameter. To quantify SFTPC+ or ACT+ spher-
oids, immunoﬂuorescence-stained day 14 organoid cultures wereman-
ually analyzed for expression using a ﬂuorescence microscope at 40×
magniﬁcation. N150 organoids were analyzed per condition per inde-
pendent experiment.
2.7. Immunoﬂuorescence
Organoid cultures were washed once with PBS, ﬁxed with ice-cold
acetone/methanol (1:1) for 12 min at -20 °C, washed again with PBSand blocked in PBS with 5% (w/v) BSA. Whole-mount immunoﬂuores-
cence was performed with antibodies diluted in PBS with 0·1% (w/v)
BSA and 0·1% Triton-X100. Cultures were incubated with primary
antibodies at 4 °C overnight, washed 3× in PBS for 15 min each, and in-
cubated with secondary antibodies at 4 °C overnight. Cultures were
excised and mounted on glass slides with ﬂuorescent mounting media
containing DAPI (Abcam #104139) and glass coverslips. Immunoﬂuo-
rescence was visualized using a Leica SP8 (Leica) confocal microscope.
Images were obtained with LASX (Leica) software. Secondary antibody
speciﬁcity was conﬁrmed by absence of signal in control samples
stainedwithout primary antibody. For quantiﬁcation of SFTPC+pixel in-
tensity and ACT+ area fraction, confocal cross-section images of individ-
ual organoidswere takenwith identical contrast andbrightness settings
across treatment groups and imported into Image J. The outside perim-
eter of each organoid was used to deﬁne the region of interest for anal-
yses. Antibodies used are listed in Table S2.
2.8. Re-sorting cells from organoid cultures
For re-sorting experiments, 200,000 mouse EpCAM+ cells and
200,000 Mlg cells were seeded in 1 ml Matrigel diluted 1:1 with
organoid culture medium into 6 well plates, and organoid culture me-
diumwasmaintained on top. At the indicated timepoints, organoid cul-
tures were digested with dispase for 30 min at 37 °C, and transferred to
15 ml tubes, washed with PBS, and digested further with trypsin for
5 min at 37 °C, prior to incubation with EpCAMmicrobeads (Miltenyi)
and passed through LS columns. The EpCAM+ and EpCAM− cell frac-
tions were both used for RNA isolation and qRT-PCR analysis.
2.9. Quantitative real-time polymerase chain reaction (qRT-PCR)
RNA was extracted from washed cell pellets using TriReagent (Life
Technologies #AM9738) and trimethylene chlorobromide ([BCP],
Sigma #B9673) followed by washing in isopropanol and elution in
30 μl RNAse-free ddH2O. Total RNA concentrations were determined
with a NanoDrop ND-1000 spectrophotometer. cDNA was synthesized
using AMV reverse transcriptase (Promega, #A3500), and diluted with
ddH2O proportionately according to concentration of input RNA. qRT-
PCR was performed with SYBR green (Roche, #04913914001) using
Illumina Eco Real-Time PCR system. PCR cycling was follows: 94 °C for
30s, annealing at 60 °C for 30s, and extension at 72 °C for 30s, for
40 cycles. qRT-PCR data were analyzed with LinRegPCR analysis soft-
ware [42,43]. Geometric mean of the reference genes beta-2-
microglobulin (B2M) and ribosomal protein L13A (RPL13A) was used
to normalize qRT-PCR data. Primer sequences are listed in Table S3.
2.10. Statistical analysis
Data were analyzedwith GraphPad Prism 5·0. Data are presented as
mean ± SEM, or median (interquartile range) within the text. N refers
to number of independent experiments starting from an independent
EpCAM+ isolation, and n refers to number of organoids. The statistical
tests used are stated in the Figure legends. A value for p of b0·05 was
considered signiﬁcant.
3. Results
We investigated the regulation of adult lung epithelial progenitor
growth and differentiation using an in vitro organoid (spheroid) assay,
in which adult mouse distal lung EpCAM+ epithelial cells were
co-cultured with Mlg (CCL206) mouse lung ﬁbroblasts in Matrigel
(Fig. 1A) [5,40,41]. Organoids formed with an efﬁciency of 1·1 ± 0·1%
per initial cells seeded, with distinct morphologies discernable by day
14 (Fig. S1A, 1B). Organoids exhibitedmorphology and immunoﬂuores-
cence staining characteristic of alveolar (proSFTPC+/ACT−; Fig. 1B'), air-
way (proSFTPC−/ACT+; Fig. 1B") ormixed alveolar/airway (proSFTPC+/
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± 5% were alveolar, 8·5± 3%were airway, 6·8 ± 3% were mixed alve-
olar/airway, and 12·7 ± 4% expressed neither marker (Fig. S1B).
Organoid cultures were incubated with pharmacological RA modu-
lators and organoid number and diameter was measured at day 7 and14, respectively (Fig. 1C). Organoids formed both in normal organoid
media (containing 10 nM ATRA) and in ATRA-free media. ATRA-free
media did not affect organoid size at day 14 compared to normal
organoidmedia (Fig. S1C).When cultured in ATRA-freemedia, stimula-
tion with ATRA (100 nM) from day 0 onwards signiﬁcantly decreased
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[100 nM] 44·6(36·1–66·5)μm, p b 0·0001; Fig. 1D,E). When catego-
rized bymorphology, the effect of ATRAwas comparable in alveolar, air-
way andmixed alveolar/airway structures (Fig. S1D). Organoid number
was not affected by ATRA (Fig. 1F). When cultured in normal organoid
media, RA pathway inhibition with the pan-RAR inverse agonist
BMS493 signiﬁcantly increased organoid size (BMS493 [0 nM] 53·2
(41–76)μm; BMS493 [100 nM] 66·2(47·9–95·2)μm; BMS493 [2 μM]
80·2(57·4–118·3)μm; both p b 0·0001 vs [0 nM]; Fig. 1G,H). BMS493
increased size of alveolar, airway and mixed alveolar/airway structures
(Fig. S1E). Organoid number was not affected by BMS493 (Fig. 1I).
To investigate the potential of RA pathway inhibition to promote
human lung epithelial regeneration in COPD, EpCAM+ cells were iso-
lated from distal lung tissue obtained from 4 patients with moderate
to severe COPD (GOLD Stage II-IV, patient characteristics are in
Table S1) and cultured together with MRC5 human lung ﬁbroblasts in
Matrigel, which resulted in organoids forming with an efﬁciency of
0·54 ± 0·2%. Immunoﬂuorescence staining of human lung organoids
at day 21 revealed positive staining for E-cadherin and β-tubulin indi-
cating airway epithelial differentiation; proSFTPC could not be detected
(Fig. 1J). Treatment with BMS493 reduced the frequency of smaller
organoids (50-100 μm diameter) and increased the frequency of larger
organoids (100-200 μmand N 200 μm; Fig. 1K, L). BMS493 did not affect
organoid number (Fig. 1M). These data indicate that RA signaling is a
conserved mechanism controlling growth of adult distal lung epithelial
progenitor cells, and suggest that RA pathway inhibition can promote
growth of epithelial progenitor cells in COPD lung.
3.1. RA pathway component gene expression during post-pneumonectomy
lung regeneration
Our ﬁndings suggest that decreased RA pathway activity may corre-
late with epithelial proliferation during adult lung regeneration in vivo.
We therefore interrogated a published microarray dataset of mouse
lung samples taken either before (day 0) or at various time points fol-
lowing surgical pneumonectomy (day 3, 7, 14, 28, 56), to assess gene
expression of RA receptors and proliferation markers during adult
lung regeneration in vivo (GEO accession number GSE39817 [44],).
Data from samples taken 56 days after sham surgery were included
for comparison. Data are from cardiac and medial lobes, which exhibit
the greatest growth and DNA synthesis following pneumonectomy
[44]. As expected, proliferation markers (Mki67, Cdk1, Ccnb1, Mcm3,
Mcm7) showed a clear upregulation at early time points compared to
day 0, peaking at days 3 and 7, and normalizing to near baseline levels
from day 14 onwards (Fig. S2A). Rara expression was relatively stable
throughout the time course (Fig. S2B). Interestingly, Rarb expression
showed the inverse trend to proliferationmarkers with a clear decrease
from day 3 to 14, normalizing to near baseline levels from day 28 on-
wards (Fig. S2B). Rarg expression showed a modest decrease in the car-
diac lobe at days 3 and 7 and a slight decrease in the medial lobe at day
3, normalizing thereafter (Fig. S2B). Gene expression trends in cardiacFig. 1. Retinoic acid signaling controls adult mouse and human distal lung epithelial organo
Representative low magniﬁcation light microscopy image of organoid culture at day 14
magniﬁcation examples of B') alveolar, B") airway, and B"’) mixed alveolar/airway morpholog
for pro-surfactant protein C (SFTPC, green), acetylated tubulin (ACT, red), and DAPI (blue).
treatment on size and number of organoids cultured in ATRA-free media. D) Representative li
μM). Scale bar = 200 μm. E) Quantiﬁcation of organoid size at day 14 following treatment
independent isolations. Mann Whitney test, *** p b 0·001. F) Quantiﬁcation of organoid numb
G-I) Effect of RA pathway inhibition with the pan-RAR inverse agonist BMS493 on size an
microscopy images of organoid cultures treated with DMSO or with BMS493 (0·1 μM, 2 μM
without or with BMS493 (0·1 μM, 2 μM). n N 570 organoids per group from N = 5 indepen
organoid number at day 7 treated without or with BMS493. Kruskall Wallis with Dunn's post
human organoids at day 21 stained for E-cadherin (green) and β-tubulin (red), with DA
Representative light microscopy images of human organoids at day 21 cultured with BMS493
100-200 μm (grey bars), or N 200 μm (black bars) in diameter measured at day 21 after trea
from 4 separate donors. M) Organoid colony forming efﬁciency of human organoids at day 14
not signiﬁcant compared to BMS493 0 nM. N= 4 donors.andmedial lobes were largely comparable for all genes. These data pro-
vide support to the notion that transient decrease in RA pathway activa-
tion is permissive for epithelial proliferation during adult lung
regeneration in vivo.
3.2. RA signaling balances adult lung epithelial proliferation and
differentiation
To investigate mechanisms of BMS493-induced lung organoid
growth, treated mouse lung organoid cultures were enzymatically dis-
sociated, and EpCAM+ cells and ﬁbroblasts were MACS-separated and
subjected to gene expression analyses (Fig. 2A). RT-qPCR for themesen-
chymal marker Vim and the epithelial marker Cdh1 on re-sorted cell
fractions revealed enrichment for each cell type in their respective frac-
tion (Fig. S3A). Re-sorting efﬁciency did not signiﬁcantly differ between
BMS493- or DMSO-treated cells (Fig. S3A). In both EpCAM+ and ﬁbro-
blast fractions re-isolated at day 7, BMS493 (2 μM)decreasedmRNA ex-
pression of the RA pathway target gene Rarb (6·7 fold decrease in
EpCAM+ cells, 7·5 fold decrease in ﬁbroblasts, both p b 0·001 vs con-
trol; Fig. 2B), which contains a RARE in its promoter region [45],
conﬁrming inhibition of RA signaling in both epithelial cells and ﬁbro-
blasts by BMS493. As ﬁbroblasts were proliferation-inactivated prior
to culture, we investigated expression of cell cycle-related genes in
EpCAM+ cells; BMS493 increased expression of Cdk1, Ccnb1, Ccnd1
(Fig. 2C). RT-qPCR for cell survival regulators revealed that BMS493
decreased expression of the pro-apoptotic factor Bik in EpCAM+ cells
(p b 0·05 compared to DMSO; Fig. 2D), but did not alter Bcl2 or Bax ex-
pression (Fig. 2D). Immunoﬂuorescence staining of day 7 organoid cul-
tures revealed enrichment of Ki67+ cells in both proSFTPC+ and
proSFTPC− organoids in BMS493-treated cultures compared to DMSO
control (Fig. 2E), conﬁrming induction of epithelial proliferation by
BMS493.
We next investigated differentiation in lung organoid cultures. In
EpCAM+ cells re-isolated from control cultures at day 14, the most
abundant transcript was Sftpc (Fig. S3B), in line with the predominance
of alveolar organoids in culture (Fig. S1B). The next abundant were
Scgb1a1 and FoxJ1 (Fig. S3B), suggesting the presence of airway
organoids undergoing secretory and ciliated cell differentiation. Trp63
and Pdpn mRNA were detected at low levels, and Muc5ac mRNA was
barely detected (Fig. S3B). BMS493 signiﬁcantly decreased expression
of Sftpc, Pdpn, Scgb1a1 and FoxJ1 (all p b 0·05 compared to DMSO con-
trol; Fig. 2F), whereas Trp63 showed a trend to decrease after BMS493,
andMuc5acwas unchanged, which may reﬂect very low expression at
baseline (Fig. 2F).
In organoids cultured in ATRA-free media, quantitative immunoﬂu-
orescence revealed addition of ATRA caused an increase in the propor-
tion of proSFTPC+/ACT− alveolar organoids that did not reach
statistical signiﬁcance (ATRA [0 nM] 56·7 ± 4%, ATRA [100 nM] 70·1
± 3%, p = 0·0657; Fig. 2G), with a concomitant signiﬁcant decrease
in proSFTPC−/ACT− organoids (ATRA [0 nM] 25·5 ± 3%, ATRA
[100 nM] 12·1±1%, p b 0·05; Fig. 2G). ATRA-freemedia also decreasedid growth. A) Schematic of mouse organoid experimental setup, based on [5,40,41]. B)
, with distinct morphologies highlighted. Scale bar = 200 μm. Representative high
ies by light microscopy (top) with corresponding immunoﬂuorescence staining (bottom)
Scale bars = 50 μm (top), 20 μm (bottom). C) Experimental plan. D-F) Effect of ATRA
ght microscopy images of organoid cultures treated with DMSO or with ATRA (0·1 μM, 1
with DMSO or with ATRA (10 nM, 100 nM). n N 510 organoids per group from N = 5
er at day 7 treated with DMSO or with ATRA. Mann Whitney test, § p = not signiﬁcant.
d number of organoids cultured in media with 10 nM ATRA. G) Representative light
). Scale bar = 200 μm. H) Quantiﬁcation of organoid size at day 14 following treatment
dent isolations. Kruskall Wallis with Dunn's post test, *** p b 0·001. I) Quantiﬁcation of
test, § p = not signiﬁcant compared to BMS493 0 μM. J) Immunoﬂuorescence images of
PI (blue) as nuclear counterstain. Scale bars = 50 μm (top), 100 μm (bottom). K)
(0, 1, 10 nM). Scale bars = 80 μm. L) Proportion of organoids 50-100 μm (white bars),
tment with BMS493 (0, 10 nM, 10 nM). Bars represent sum of organoid counts pooled
after treatment with BMS493 (0, 1, 10 nM). Kruskall Wallis with Dunn's post test, § p =
Fig. 2. Retinoic acid signaling balances lung progenitor cell proliferation and survival, and differentiation. A) Strategy to re-sort epithelial cells from ﬁbroblasts in organoid cultures. B) RT-
qPCR for Rarb in EpCAM+ and ﬁbroblast cells re-sorted at day 7, following either DMSO (white bars) or BMS493 (2 μM, black bars) treatment. N= 4 independent isolations. Unpaired t-
test, ** p b 0·001 compared to corresponding DMSO control. C-D) RT-qPCR for C) cell cycle genes Cdk1, Ccnb1 and Ccnd1, and D) cell survival genes Bcl2, Bik and Bax, in EpCAM+ cells re-
sorted at day 7 followingDMSO (white bars) or BMS493 (2 μM, black bars) treatment. N=4 independent isolations. Paired t-test, * p b 0·05 compared to corresponding DMSO control. E)
Representative immunoﬂuorescence images of Ki67 staining (white) in organoids at day 7, showing enrichment (white arrows) in organoids following BMS493 treatment, in both alveolar
(ProSFTPC+, red), and non-alveolar organoids. DAPI (blue)was used as a nuclear counterstain (blue). Scale bar= 50 μm. F) RT-qPCR on EpCAM+ cells re-sorted from organoid cultures at
day 14, showing effect of RA inhibitionwith BMS493 (2 μM, black bars) onmRNA expression ofmarkers of speciﬁc lung cell types, compared to DMSO (white bars).N=3–4 independent
isolations. Unpaired t-test *p b 0·05, **p b 0·01 compared to correspondingDMSO control. G) Effect of ATRA (0, 100 nM, added to ATRA-freemedia) on proportion of organoids expressing
SFTPC and/or ACT. N= 3 independent isolations. Unpaired t-test of total SFTPC+ organoids, *p b 0·01. H) Effect of BMS493 (0, 0·1, 2 μM, added to normal culturemedia) on proportion of
organoids expressing SFTPC and/or ACT. N = 3 independent isolations. One way ANOVA of SFTPC+/ACT− organoids with Dunnett's post test, *p b 0·05. I) Representative immunoﬂuo-
rescence images of day 14 organoid cultures treated with ATRA or BMS493, for SFTPC (green), ACT (red) and DAPI (blue). Scale bars = 100 μm. J) Digital quantiﬁcation of ACT+ area
per organoid after BMS493 (2 μM) treatment. n N 46 organoids from 2 independent isolations. MannWhitney test, **p b 0·01.
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J.-P. Ng-Blichfeldt et al. / EBioMedicine 36 (2018) 461–474the proportion of alveolar organoids compared to normal organoid
culture media (Fig. S4). Furthermore, when added to normal cul-
ture media, BMS493 decreased the proportion of alveolar organoids
(BMS493 [0 μM] 75·2 ± 6%, BMS493 [0·1 μM] 58·4 ± 4%, BMS493
[2 μM] 40·1 ± 9%, [2 μM] p b 0·05 compared to [0 μM]; Fig. 2H),
and increased the proportion of proSFTPC−/ACT− organoids
(BMS493 [0 μM] 11·5 ± 5%, BMS493 [0·1 μM] 28·2 ± 4%,
BMS493 [2 μM] 51·5 ± 12%, [2 μM] p b 0·05 compared to [0 μM];
Fig. 2H). Additionally, proSFTPC staining intensity was increased
by ATRA, and decreased by BMS493 (Fig. 2I). The proportion of
proSFTPC−/ACT+ or proSFTPC+/ACT+ organoids was unchanged
by either ATRA or BMS493 (Fig. 2H). However, BMS493 treatment
signiﬁcantly reduced the ACT+ area per organoid, indicating re-
duced numbers of airway ciliated cells (BMS493 [0 μM] 15·9
[7–32]%, BMS493 [2 μM] 4·8 [2–46]%, p b 0·01; Fig. 2I, J). Alto-
gether, these data suggest RA pathway inhibition promoted adult
distal lung epithelial progenitor cell proliferation while suppressing
proper alveolar and airway differentiation, whereas RA pathway
stimulation had the inverse effects.Fig. 3.Retinoic acid signaling controls lung organoid size via epithelial yes-associated protein (Y
A) YAP pathway target genes, or B) Yap and Taz, following treatmentwith DMSO vehicle (white
**p b 0·01 compared to corresponding DMSO control. C) Representative immunoﬂuorescenc
(green), and Ki67 (white), showing an alveolar (top) and non-alveolar (bottom) organoid. D
proportion of organoids exhibiting nuclear Yap protein following ATRA (0, 100 nM, added to
Kruskal Wallis with Dunn's post test, *p b 0·05. E) Organoid diameter, measured at day 1
verteporﬁn (4 μM) alone in combination. n N 545 organoids per group, N = 5 independent iso3.3. RA pathway inhibition promotes lung organoid proliferation via YAP
pathway activation
To investigate downstream molecular pathways that mediate in-
creased lung epithelial growth after RA pathway inhibition, we focused
on Yes-associated protein (YAP), a transcriptional co-activator that con-
trols organ size during development by regulating gene expression to-
gether with the TEAD family of nuclear transcription factors [46,47].
RT-qPCR for a selection of YAP target genes [48] revealed activation of
YAP signaling in EpCAM+ cells by BMS493 (Tead4, Kif23, Polh, Ccna2 p
b 0·05, and Cdca5, Cdca8 p b 0·01 compared to DMSO control;
Fig. 3A). Gene expression of Yap and the closely related transcriptional
co-activator Tazwere unchanged by BMS493 (Fig. 3B). We used immu-
noﬂuorescence for YAP protein to investigate subcellular localization,
which revealed nuclear YAP localization and thus YAP pathway activa-
tion in both proSFTPC+ and proSFTPC− organoids following BMS493,
where it frequently co-localizedwithKi67 (Fig. 3C). Quantitative immu-
noﬂuorescence showed that ATRA decreased the proportion of
organoids at day 7 with nuclear YAP (ATRA [0 nM] 41·3 ± 17%, ATRAAP) pathway. A-B) RT-qPCR on EpCAM+ cells re-sorted from organoid cultures at day 7, for
bars) or BMS493 (2 μM; black bars). N=4 independent isolations. Paired t-test, *p b 0·05,
e images of day 14 organoid cultures treated with BMS493 (2 μM), for SFTPC (red), Yap
API was used as a nuclear counterstain (blue). Scale bars = 50 μm. D) Quantiﬁcation of
ATRA-free media, left), or BMS493 (0, 0·1, 2 μM added to normal culture media, right).
4, following treatment with DMSO, or BMS493 (2 μM) or the Yap pathway inhibitor
lations. Kruskall Wallis with Dunn's post test, *** p b 0·001.
Fig. 4. Fibroblast-epithelial FGF-FGFR2b signaling contributes to growth induced by RA inhibition. A) RT-qPCR for A) Fgf7 and B) Fgf10 in EpCAM+ and ﬁbroblast cells re-sorted at day 7,
following either DMSO (white bars) or BMS493 (2 μM, black bars) treatment. N=4 independent isolations. Paired t-test, *pb 0·05, ** p b 0·001 compared to correspondingDMSOcontrol.
C-D) RT-qPCR on EpCAM+ cells re-sorted from organoid cultures at day 7, for C) FGFR2b target genes, or D) Fgfr2b, following treatmentwith DMSO vehicle (white bars) or BMS493 (2 μM;
black bars). N= 4 independent isolations. Paired t-test, n.s. = not signiﬁcant. *p b 0·05, **p b 0·01 compared to corresponding DMSO control. E) Organoid diameter, measured at day 14,
following treatment with DMSO control, or BMS493 (100 nM) or the pan-FGFR inhibitor CH5183284 (100 nM) alone or in combination. n N 374 organoids per group, N= 3 independent
isolations. Kruskall Wallis with Dunn's post test, *p b 0·05, *** p b 0·001. F) Organoid diameter, measured at day 14, following treatment with vehicle, recombinant FGF7 (50 ng/ml) or
recombinant FGF10 (100 ng/ml). n N 900 organoids per group, N = 3 independent isolations. Kruskall Wallis with Dunn's post test, *** p b 0·001. G) Representative light microscopic
images of day 14 organoid cultures showing effect of recombinant FGF7 and FGF10 on organoid size (arrowheads). Scale bars = 80 μm.
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organoids with nuclear YAP (BMS493 [0 μM] 27·2 ± 9%, BMS493 [0·1
μM] 43·0 ± 11, BMS493 [2 μM] 52·1 ± 10%, BMS [2 μM] p b 0·05 com-
pared to BMS [0 μM]; Fig. 3D). Together, these data indicate that RA in-
hibition with BMS493 leads to epithelial YAP pathway activation.
We next investigated the role of YAP pathway in BMS493-induced
epithelial proliferation by treating organoid cultures with BMS493
(2 μM) or the YAP pathway inhibitor verteporﬁn (4 μM) [49] alone or
combined. Verteporﬁn alone had no effect on organoid size or number
compared to DMSO control (Fig. 3E and data not shown), whereas
verteporﬁn prevented BMS493-induced increase in organoid size
(BMS493 84·4(60–121)μm, BMS493 + verteporﬁn 67·0(49–110)μm,
p b 0·001; Fig. 3E). These data suggest that RA inhibition promotes
mouse lung organoid growth via YAP nuclear translocation and tran-
scription of YAP target genes.
3.4. Fibroblast-epithelial FGF signaling contributes to lung organoid growth
after RA inhibition
The presence of both epithelial cells and ﬁbroblasts in organoid cul-
tures raised the possibility that RA inhibition caused epithelial growth
via indirect effects on ﬁbroblasts. FGF7 and FGF10 are mesenchyme-
derived signaling molecules important for epithelial growth during
lung development and adult lung repair [40,50–53], and in mouselung development, RALDH2 downregulation, causing reduced RA sig-
naling, induced FGF10 in the distal tipmesenchyme to allow proper ep-
ithelial branching [16]. We therefore focused on ﬁbroblast-epithelial
FGF signaling as a potential mechanism of BMS493-induced lung
organoid growth. BMS493 signiﬁcantly increased gene expression of
both Fgf7 and Fgf10 in ﬁbroblasts re-isolated from organoid cultures at
day 7 (p b 0·05 compared to DMSO control; Fig. 4A, B). BMS493 also
caused a modest signiﬁcant induction of Fgf10 in the EpCAM+ fraction
(p b 0·05; Fig. 4B). BMS493 induced expression of FGFR2b pathway
target genes [54] within the EpCAM+ fraction (Timp3 p b 0·01, Ctsh p
b 0·05, Tacstd2 p b 0·05, Tmod3 p = 0·08, BMS493 compared to
DMSO control; Fig. 4C). Gene expression of Fgfr2b was unchanged by
BMS493 (Fig. 4D). These data suggest that FGF7/10-FGFR2b ﬁbroblast-
epithelial signalingmay contribute to growth induction by RA pathway
inhibition. To investigate this, organoid cultures were treated with
BMS493 (100 nM) or the FGFR inhibitor CH5183284 (100 nM), alone
or in combination, for 14 days. CH5183284 alone did not affect organoid
size compared to DMSO control (Fig. 4E), whereas CH5183284 partially
prevented BMS493-induced increase in organoid size (BMS493 63·2
(51–84)μm, CH5183284 + BMS493 61·4(45–83)μm, p b 0·05;
Fig. 4E). Next, the effect of recombinant human FGF7 and FGF10 on
organoid size was investigated. Recombinant FGF7 led to a signiﬁcant
increase in organoid size compared to vehicle control (vehicle 59·3
(50–76)μm, FGF7 80·0(62–112)μm, p b 0·001; Fig. 4F, G). FGF10 also
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FGF7 (FGF10 64·8(52–90)μm, p b 0·001; Fig. 4F, G). These data provide
further support for the notion that enhanced epithelial growth inmouse
lung organoids following RA pathway inhibition may be mediated in
part by ﬁbroblast-epithelial FGF signaling.
3.5. HDAC inhibition as a strategy to rescue lung epithelial differentiation
after RA inhibition
We next investigated strategies to rescue organoid differentiation
following pharmacological RA pathway inhibition. BMS493 inhibits RA
signaling by stabilizing the association between DNA-bound RAR/RXR
heterodimers and nuclear receptor co-repressor (NCoR) [55], part of a
co-repression complex that contains histone deacetylases (HDACs).
HDACs mediate transcriptional repression by maintaining chromatin
in a condensed state. We reasoned that after BMS493 treatment, subse-
quent addition of a pharmacological HDAC inhibitor would inhibit the
activity of the stabilized co-repression complex, permitting chromatin
remodeling and de-repression of RA target genes and thus enable
proper differentiation. To investigate this, organoid cultures were
treated with BMS493 for 14 days, or for 7 days followed by a washout
period with culture media containing either 10 nM ATRA or 100 nM
ATRA, supplemented either with DMSO orwith the pan-HDAC inhibitor
SAHA (Fig. 5A). Organoid cultures treatedwithDMSO for 14 days served
as controls. All treatment groups led to signiﬁcantly increased organoid
size compared to DMSO control (all p b 0·001 compared to DMSO;
Fig. 5B). Notably, the size of organoids in cultures treated with
BMS493 for 14 days was not signiﬁcantly different to those treated for
7 days (Fig. 5B). Additionally, SAHA treatment from day 7 did not
have a signiﬁcant effect on organoid size compared to the correspond-
ing DMSO control (Fig. 5B). Morphologically, BMS493 treatment for
14 days gave rise to organoidswith a dark, dense appearancewith irreg-
ular edges suggestive of an immature state (Fig. 5C). Reducing BMS493
treatment to 7 days followed by a 7 daywashoutwith 100 nMATRA did
not restore organoid morphology. However, treatment with SAHA
+100 nMATRA from day 7 restored organoids to regular morphologies
observed in control cultures (Fig. 5C).
BMS493 treatment for 14 days strongly reduced Rarb expression in
the EpCAM+ fraction (p b 0·001 compared to DMSO control; Fig. 5D).
Notably, 7 days of BMS493 treatment followed by 7 day washout with
either 10 nM or 100 nM ATRA did not restore Rarb expression, indicat-
ing lasting repression of RA signaling by BMS493, likely via epigenetic
silencing. Addition of SAHA to mediumwith 10 nM ATRA had no effect
on Rarb expression. However, addition of SAHA to medium containing
100 nM ATRA signiﬁcantly increased Rarb expression (p b 0·01 com-
pared to BMS493 [14 days]; Fig. 5D), indicating partial restoration of
RA signaling. We therefore investigated the impact of BMS493washout
with SAHA+100 nM ATRA on organoid differentiation.
RT-qPCR revealed repression of Sftpc, Scgb1a1, FoxJ1 and Pdpn gene
expression by 14 days BMS493 treatment, which was not restored by
washout with 100 nM ATRA alone (Fig. 5E). Interestingly, washout
with SAHA +100 nM ATRA from day 7 led to a signiﬁcant increase in
Scgb1a1 mRNA expression (p b 0·05 compared to BMS493 [14 days];
Fig. 5E). Sftpc, FoxJ1 and Pdpn expression were not changed by SAHA
(Fig. 5E). Muc5ac gene expression was unchanged by 14 days of
BMS493 or 7 days of BMS493 followed by 7 day washout with 100 nM
ATRA, but was signiﬁcantly decreased by SAHA +100 nM ATRA (p b
0·05 compared to BMS493 [14 days]; Fig. 5E).
Immunoﬂuorescence and digital quantiﬁcation of proSFTPC+ stain-
ing intensity revealed that BMS493 followed by washout reduced
proSFTPC protein expression (Fig. 5F; DMSO 117·3(82–223), BMS493
64·7 [42–84], p b 0·001; Fig. 5G). Addition of SAHA in the washout pe-
riod signiﬁcantly increased proSFTPC protein (SAHA 93·0(67–135), p b
0·01 SAHA compared to BMS493 alone; Fig. 5G), suggesting that SAHA
rescued AT2 differentiation following RA pathway suppression. SAHA
did not affect the proportion of proSFTPC+ organoids (Fig. 5H).Unexpectedly, SAHA treatment induced protein expression of the club
cell marker SCGB3A2 in proSFTPC− organoids, which was not observed
either in cultures treated with DMSO or BMS493 alone (SAHA 2·3 ±
0·2%, p b 0·001 compared toDMSO and BMS493; Fig. 5F, H). Altogether,
these data suggest that HDAC inhibition combined with ATRA restored
RA signaling following BMS493 treatment, and rescued differentiation
of AT2 and club cells.
4. Discussion
RA signaling has received interest as a potential therapeutic target
for chronic lung diseases, in part due to pre-clinical studies using
in vivomodels of COPD/emphysema that found induction of alveolar re-
generation by ATRA administration [25–32]. The failure of retinoids in
clinical trials for emphysema patients has been difﬁcult to explain
[33–36], in part because the speciﬁc role of RA signaling in adult distal
lung epithelial progenitor cells has been little explored. Using an adult
lung epithelial organoid model, we unexpectedly found that ATRA de-
creased lung organoid size, whereas RA pathway inhibition increased
size of mouse lung organoids and of organoids derived from COPD pa-
tient lung tissue. In mouse lung organoids, RA inhibition augmented
lung epithelial proliferation while suppressing airway and alveolar dif-
ferentiation, and was mediated by epithelial YAP pathway activation
and ﬁbroblast-epithelial FGF signaling. HDAC inhibition combined
with ATRA restored RA signaling and rescued alveolar and airway differ-
entiation. Thus, rather than RA pathway stimulation, our study suggests
therapeutic potential for controlled, transient RA pathway inhibition
followed by pharmacological induction of differentiation to promote
lung epithelial regeneration in chronic lung diseases.
Our ﬁndings are surprising, as induction of alveolar regeneration by
ATRA in vivo presumably requires lung epithelial proliferation [25–32].
A possible explanation is that adult lung cell types present in vivo but
not represented in the organoid assay could modulate the epithelial re-
sponse to ATRA. An inherent limitation of the organoid assay is loss of
cell-cell contacts between epithelial cells and other lung cell types in-
cluding endothelial and immune cells; for example, lung endothelial
cells instructed alveolar differentiation of epithelial cells in organoid
co-cultures [56]. An alternative explanation is that ATRA administration
in vivo could cause a transient increase in RA pathway inhibition via in-
duction of CYP26 enzymes that catalyze the breakdown of RA; CY26A1
is highly inducible by RA due to presence of multiple RAREs in its pro-
moter region [57]. In mouse embryos, ATRA administration paradoxi-
cally phenocopied the teratogenic effects of targeted RALDH2 or
compound RAR disruptions, through induction of CYP26A1 and
CYP26B1 and consequent RA pathway inhibition [58–60]. Consistent
with the idea that RA pathway inhibition is permissive for epithelial
proliferation in vivo, our analysis of a published microarray dataset
[44] revealed that decreased Rarb expression coincided with the prolif-
erative phase of post-pneumonectomy lung regeneration.
The transcriptional program induced by RA is highly developmental
stage and cell type speciﬁc, and may promote or inhibit growth of adult
cells depending on cell type [14]. Our ﬁndings suggest RA signaling re-
presses growth of normal adult distal lung epithelial progenitor cells,
as has previously been shown in small cell lung cancer cells [61] and im-
mortalized human bronchial epithelial cells [62]. BMS493 increased size
but did not affect number of epithelial organoids derived from resected
lung tissue from COPD patients, suggesting conservation of this mecha-
nism in adult human lung epithelium. Notably, BMS493 strongly re-
pressed Rarb expression. While Rarb expression is widely used to
report RA pathway activity due to an RARE in its promoter region [45],
RARβ is also recognized as a tumor suppressor [63–65] and its expres-
sion is frequently perturbed in human lung cancer [66,67]. The speciﬁc
transcriptional repertoire controlled by RARβ has yet to be fully charac-
terized in lung epithelial progenitor cells. RA inhibition in lung
organoids reduced expression of Bik, which encodes a pro-apoptotic
member of the Bcl2 family of cell survival proteins [68], suggesting RA
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tent with this, ATRA induced Bik expression in acute promyelocytic leu-
kemia cells [69] and regulated expression of other Bcl2 family members
in various cancer cell types [63].
Our ﬁndings suggest YAP pathway activation contributed to aug-
mented epithelial proliferation in mouse lung organoids following RA
pathway inhibition. The YAP pathway appears to be a common nodal
point integrating pro-growth stimuli, as YAP activation regulated AT2
cell proliferation during lung regeneration following pneumonectomy
in adultmice [70], and promoted adultmouse airway epithelial cell pro-
liferation in vivo and in vitro [71–73]. Notably, YAP hyperactivity is
widely associated with human malignancies including lung cancer
[74], and YAP activation contributed to lung cancer progression in
adult mice in vivo [75,76]. The mechanism by which RA signaling re-
stricts YAP activity to control lung epithelial proliferation is currently
unclear. We found that FGFR inhibition partially prevented mouse
lung organoid growth induced by BMS493, and recombinant FGF7 and
FGF10 mirrored the effect of BMS493, suggesting that RA inhibition
may drive YAP pathway activity via ﬁbroblast-derived FGF7 and FGF10
signaling to epithelial FGFR2b. Additionally, BMS493 induced Fgf7 and
Fgf10 gene expression in ﬁbroblasts, suggesting RA signaling normally
represses their expression in lung mesenchyme. Consistent with this,
Raldh2 downregulation was required for mesenchymal Fgf10 induction
in the distal tip of branching airways during mouse lung development
[16]. FGFR2-mediated signaling was previously described to interact
with YAP and control its activity [77], however, other transcription fac-
tors and signaling molecules may also function downstream of RA sig-
naling to control YAP activity [78]. Further studies using human
models are needed to investigate the relevance of YAP and FGFR-
mediated pathways downstream of RA signaling in human lung
epithelium.
RA pathway modulation affected the proportion of alveolar
organoids and the number of ACT+ ciliated cells per organoid, implicat-
ingRA signaling in the control of adult alveolar and airway epithelial dif-
ferentiation. This is in line with described effects of RA pathway
activation in inducing differentiation of both embryonic and adult
stem/progenitor cell types [79–83]. RA is well known to promote
mucociliary differentiation of adult airway epithelial cells in vitro
[84,85], and RA deﬁciency in adult rats caused airway epithelial squa-
mous metaplasia that was reversed by vitamin A supplementation
[86]. Further investigations into RAR subtypes that control alveolar
and airway differentiation in adult lung epithelial cells may aid in devel-
opment of speciﬁc, targeted retinoid lung regenerative therapies.
Typically, ATRA binding to RAR/RXR heterodimers displaces
co-repressors for a co-activator complex containing histone acetyltrans-
ferases (HATs) to allow chromatin remodeling at receptor-targeted loci
and enable transcription [14]. BMS493washout followed by addition of
100 nMATRAdid not restore expression of RARb or of lung epithelial cell
markers, suggesting that BMS493 caused lasting chromatin compaction
at genes required for differentiation [55]. Accordingly, HDAC inhibition
combined with ATRA partially restored RARb expression in BMS493-
treated organoids, and increased protein expression of proSFTPC and
SCGB3A2, suggesting restoration of alveolar and airway differentiation.
Notably, HDACs enhanced the differentiation-inducing ability of RA inFig. 5. HDAC inhibition promotes differentiation following RA inhibition-induced growth. A)
DMSO or the indicated treatments. n N 289 organoids per group, N = 2 independent isolatio
other between-group comparisons were not signiﬁcant. C) Representative light microscopic
treatment caused an immature organoid morphology that was not restored by a washout pe
restored organoid morphology to similar to DMSO control (white arrowheads). Scale bars =
after treatment with DMSO or the indicated treatments. N = 2–3 independent isolations. One
(d0-d14). E) RT-qPCR for lung epithelial cell type markers in EpCAM+ cells re-sorted from o
3–6 independent isolations. One way ANOVA with Dunnett's post-test, **p b 0·01, *p b 0·05 c
images of day 14 organoids showing effect of the indicated treatments on SFTPC (green) and
= 50 μm. G) Digital quantiﬁcation of SFTPC+ staining pixel intensity per organoid from day 1
isolations. Kruskall Wallis with Dunn's post test, *** p b 0·001, *p b 0·05 compared to DMS
SFTPC and/or SCGB3A2. N = 3 independent isolations. One way ANOVA with Dunnett's post teneuroblastoma in vitro and in vivo [87] and the combination of HDACs
and retinoids has been explored in clinical trials for solid tumors and he-
matologic malignancies [88,89]. Whether ATRA-induced differentiation
in adult lung epithelial progenitor cells arises through direct transcrip-
tion of RAR target genes or indirectly via secondary transcription factors
remains to be determined [90]; investigations into genome-wide chro-
matin occupancy of ATRA-RAR complexes in speciﬁc lung epithelial cell
types might be informative. Furthermore, the speciﬁc role of HDACs in
lung epithelial differentiation, and whether this is either inﬂuenced by
prior RA pathway inhibition, or depends on concomitant RA pathway
activation, warrants further study. Muc5ac expression was further re-
pressed by HDAC inhibition, suggesting goblet cell differentiation may
require HDAC activity. Additionally, inhibited differentiation after
BMS493 treatment may involve epithelial YAP pathway activation, as
YAP phosphorylation and cytoplasmic sequestration was critical for air-
way epithelial secretory and ciliated cell differentiation [71,72].
A potential limitation to our study is that BMS493promotes chroma-
tin compaction at RAR-targeted loci, and thus may repress RA target
genes that would normally be activated independent of RA signaling;
consequently, BMS493 could elicit different effects than absence of
ATRA alone. In support of an RAR-speciﬁc mechanism of BMS493, re-
duced alveolar differentiation following BMS493 mirrored the effect
ATRA-free media. However, unlike BMS493 treatment, ATRA-free
media did not signiﬁcantly affect organoid size compared to normal cul-
turemedia, which contains 10 nMATRA. Retinoids have been identiﬁed
in fetal bovine serum [91], which could have been sufﬁcient to repress
growth in absence of exogenous ATRA. Additionally, human bronchial
epithelial cells can esterify retinol for intracellular storage, which
could mitigate the effect of ATRA exclusion in our study [92]. Nonethe-
less, 100nMATRA reduced organoid size, supporting the notion that ep-
ithelial growth is controlled by RA signaling.
RA inhibition promoted growth of organoids derived from human
lung cells isolated from lung tissue from end-stage COPD patients,
supporting the idea that RA pathway inhibition may hold therapeutic
potential to induce epithelial regeneration in human severe chronic
lung disease. Further optimization of human lung organoid culture to
allow alveolar differentiation will be necessary to understand the rele-
vance of these ﬁndings to human alveolar repair. Additionally, our
data suggest potential for RA pathway inhibition for in vitro expansion
of lung epithelial progenitor cells for regenerative cell-based strategies.
Prospective selective therapies using RA pathway inhibition must be
carefully controlled to allow appropriate re-activation of RA signaling
for correct differentiation. In light of the high frequency of bothRApath-
way and YAP pathway perturbations in lung cancer [66,67,74], the
mechanism by which RA inhibition permits YAP activation and
promotes lung epithelial proliferation warrants further investigation.
In vitro, ATRA stimulated lung microvascular angiogenesis [20] and
lung ﬁbroblast elastin synthesis [21], and thus non-epithelial cellular
processes critical for lung regenerationmay require RA pathway activa-
tion. Further studies are needed to investigate the balance of RA path-
way activation and inhibition required for lung regeneration, the
timing of pathway modulation, and the speciﬁc role of RA signaling in
other relevant lung cell types. As RA pathway perturbations have been
identiﬁed in emphysematous lung tissue and cells isolated from COPDExperimental plan. B) Organoid diameter, measured at day 14, following treatment with
ns. Kruskall Wallis with Dunn's post test, *** p b 0·001 compared to DMSO control, all
images of day 14 organoid cultures showing effect of the indicated treatments. BMS493
riod with 100 nM ATRA (empty arrowheads). Addition of SAHA in the washout period
80 μm. D) RT-qPCR for Rarb on EpCAM+ cells re-sorted from organoid cultures at day 14
way ANOVA with Bonferroni's post-test, ***p b 0·001, **p b 0·01 compared to BMS493
rganoid cultures at day 14 after treatment with DMSO or the indicated treatments. N =
ompared to corresponding DMSO (14d) control. F) Representative immunoﬂuorescence
SCGB3A2 (red) protein expression, with DAPI (blue) as nuclear counterstain. Scale bars
4 organoid cultures after the indicated treatments. n N 47 organoids, N = 3 independent
O control. H) Effect of the indicated treatments on proportion of organoids expressing
st, ** p b 0·01, *p b 0·05, § = not signiﬁcant compared to corresponding DMSO control.
472 J.-P. Ng-Blichfeldt et al. / EBioMedicine 36 (2018) 461–474patients [20,24], additional studies investigating the potential of RA
pathwaymodulation to augment repair in humanmodels using epithe-
lial cells and ﬁbroblasts from COPD patients are required, particularly as
animal models of COPD may not fully recapitulate human disease [93].
Furthermore, the regenerative competence of the COPD lung, including
the extent to which relevant progenitor cell types and regenerative sig-
naling pathways remain intact in diseased lung tissue, requires better
characterization for successful application of retinoid-based regenera-
tive therapies.
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